Effect of proton-pump inhibitor therapy on serum chromogranin A level.
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Background: The neuroendocrine marker, chromogranin A (CgA) increases during medium- or long-term proton-pump inhibitor (PPI) treatment. Aims: To analyze the effect of ultra-short-term and diverse dose of PPI therapy on serum CgA and gastrin levels and evaluate the effect of PPI treatment cessation. Patients and Methods: Fasting serum CgA and gastrin were determined in newly diagnosed gastroesophageal reflux disease (GERD) patients (n = 54) treated with diverse doses of PPI during a 28-day period, in patients treated with PPIs for at least 6 months (n = 42), and in subjects where PPI treatment could be stopped (n = 11). Results: A significant stepwise increase of CgA levels was observed after 5 days during the 28-day period treatment with all PPI doses. Gastrin increased significantly also in the standard and high-dose PPI subgroups. The most prominent increase of CgA was observed in the high-dose PPI subgroup. Serum CgA and gastrin were markedly elevated after 6 months of PPI treatment, and decreased significantly after 5 days of PPI discontinuation. Conclusions: Serum CgA increases significantly even after ultra-short-term (5 days) PPI therapy. After long-term treatment, 5-day cessation of PPI therapy is sufficient to decrease significantly both CgA and gastrin levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the start of a PPI resulted in a CgA increase of about 1.5-, 2.5-, and 3-fold after 5, 10, and 28 d of PPI treatment, respectively (10).”
From Effect of Short-Term Proton Pump Inhibitor Treatment and Its Discontinuation on Chromogranin A in Healthy Subjects (2012) · cites this paper as [10]
In the citing paper
“These findings are in line with the increase in CgA in patients with gastroesophageal reflux disease in whom the start of a PPI resulted in a CgA increase of about 1.5-, 2.5-, and 3-fold after 5, 10, and 28 d of PPI treatment, respectively (10).”
From Effect of Short-Term Proton Pump Inhibitor Treatment and Its Discontinuation on Chromogranin A in Healthy Subjects (2012) · cites this paper as [10]
Citations
Cites
1 retracted
Donnellan, C., Preston, C., Moayyedi, P., & Sharma, N. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003245.pub3 · Cited by 150
RetractedThe Chromogranin–Secretogranin Family
Taupenot, L., Harper, K. L., & O'Connor, D. T. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021405 · Cited by 819
Gastro-oesophageal reflux disease
Moayyedi, P., & Talley, N. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68932-0 · Cited by 426
Long-Term Treatment with Omeprazole for Refractory Reflux Esophagitis: Efficacy and Safety
Klinkenberg-Knol, E. C., Festen, H. P. M., Jansen, J. B. M. J., Lamers, C. B. H. W., Nelis, F., Snel, P., Luckers, A., Dekkers, C. P. M., Havu, N., & Meuwissen, S. G. M. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-3-199408010-00001 · Cited by 422
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1006-3 · Cited by 387
Reimer, C., Søndergaard, B., Hilsted, L., & Bytzer, P. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.03.058 · Cited by 356
Marked increase in gastric acid secretory capacity after omeprazole treatment.
Waldum, H. L., Arnestad, J. S., Brenna, E., Eide, I., Syversen, U., & Sandvik, A. K. (1996) · Gut · doi:10.1136/gut.39.5.649 · Cited by 243
A comparison between three commercial kits for chromogranin A measurements
Stridsberg, M., Eriksson, B., Oberg, K., & Janson, E. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1770337 · Cited by 202 · cited 1×
“CgA-RIA CT’s sensitivity was 67p, specificity 96p with a positive predictive value of 97p and a negative predictive value of 63p in a comparison between three commercial kits for CgA measurement by Stridsberg et al. [”
ResultGastrin-histamine sequence in the regulation of gastric acid secretion.
Waldum, H. L., Sandvik, A. K., Brenna, E., & Petersen, H. (1991) · Gut · doi:10.1136/gut.32.6.698 · Cited by 190 · cited 1×
“BackgroundGastrin, released from antral G cells, is a main regulator of gastric acid secretion; furthermore, it has not only stimulatory but also trophic effect on gastric mucosa, especially on neuroendocrine cells, the enterochromaffin-like cells (ECL) of the stomach [”
BackgroundDiagnostic and Therapeutic Use of Proton Pump Inhibitors in Non-Cardiac Chest Pain: A Metaanalysis
Cremonini, F., Wise, J., Moayyedi, P., & Talley, N. J. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41657.x · Cited by 163
Cited by
Gastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586
Proton-pump inhibitors: understanding the complications and risks
Malfertheiner, P., Kandulski, A., & Venerito, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.117 · Cited by 297
S2k-Leitlinie Neuroendokrine Tumore: AWMF-Reg. 021-27
Authors, Collaborators:, Deutsche Gesellschaft für Gastroenterologie, V. U. S. (., (Patientenvertretung), N. N. T. (. E. V., (Patientenvertretung), B. S. N. T. E. V. (.-S., Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. (DGHO), U. A. I. O. (. D. D. K. E. V., (DGAV), D. G. F. A. U. V. E. V., (DGCH), D. G. F. C., (DGEBV), D. G. F. E. U. B. V., (DGNM), D. G. F. N. E. V., et al. (2018) · Zeitschrift für Gastroenterologie · doi:10.1055/a-0604-2924 · Cited by 180
Chromogranin A—unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
Gut, P., Czarnywojtek, A., Fischbach, J., Bączyk, M., Ziemnicka, K., Wrotkowska, E., Gryczyńska, M., & Ruchała, M. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.57577 · Cited by 144
“The PPI therapy may increase CgA concentration just 5 days after the first intake and leads to CgA 5–10 times higher than the upper reference range, results often seen in patients with early stage NET [12].”
BackgroundHvid‐Jensen, F., Pedersen, L. H., Funch-Jensen, P. M., & Drewes, A. M. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12693 · Cited by 103
“The gastrin level may increase 5–10 fold during PPI therapy, and may have anti-apoptotic and proliferative effects that contribute to neoplasia.(30) This may increase the risk of gastrointestinal tumours.”
Background
Metadata
- Authors
- Pregun, I., Herszényi, L., Juhász, M., Miheller, P., Hritz, I., Patócs, A., Rácz, K., & Tulassay, Z.
- Affiliations
- Semmelweis University (HU)
- Venue
- Digestion
- Publisher
- S. Karger AG
- Published
- 2011
- Volume
- 84
- Issue
- 1
- Pages
- 22-28
- ISSN
- 0012-2823 (ISSN-L)
- 1421-9867
- OpenAlex
- W2028774131
- Cited by
- 89
- References
- 33
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 9 · 2020: 8 · 2019: 10 · 2018: 13 · 2017: 5 · 2016: 3 · 2015: 5 · 2014: 4 · 2013: 4 · 2012: 6
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Digestion (publishedVersion)
- PubMed (publishedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
- Health Sciences › Medicine › Gastroenterology › Helicobacter pylori-related gastroenterology studies
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- proton pump inhibitors, chromogranin A, gastrin, gastroesophageal reflux disease, neuroendocrine markers, PPI discontinuation, long-term PPI therapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Gastrins, Gastroesophageal Reflux, Humans, Male, Middle Aged, Prospective Studies, Time Factors, Helicobacter pylori, Helicobacter Infections, Chromogranin A, Proton Pump Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of proton-pump inhibitor therapy on serum chromogranin A level. https://app.cochat.ai/papers/10.1159/000321535
- The paper
- Pregun, I., Herszényi, L., Juhász, M., Miheller, P., Hritz, I., Patócs, A., Rácz, K., & Tulassay, Z. (2011). Effect of proton-pump inhibitor therapy on serum chromogranin A level. Digestion. https://doi.org/10.1159/000321535
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.